Joseph Gut - thasso
Posted in Genetic Background, New Drug Approval, Pediatrics, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], Allelic Variant, Children, New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
April 23, 2017 – This is a Safety Announcement from April 20, 2017, by the American Food & Drug Administration (FDA) to the fact that FDA further restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children and recommends against their use in breastfeeding women.
…
Joseph Gut - thasso
Posted in Allelic Variant, Children, Genetic Background, In The Press, On The Horizon, Pediatrics, Thasso Post, Theragenomic Medicine
No Comments ↓
April 04, 2017 – Personalized medicine, also referred to as precision medicine, incorporates the individual patient’s characteristics into treatment, rather than relying on population means. Over the past several years, it has become a significant focus for research. Developments in pharmacogenomics, the study of genomic variations that influence response to drugs,
…
September 03, 2016 – This morning, I stumbled upon the headline of a posting on mobihealthnews, entitled “Study finds iPads and games as effective as sedatives to calm pre-op anxiety in children” and starting out with saying “The hypnotic trance kids enter when they’re staring at an iPad isn’t just for on-demand quiet time in restaurants or
cars.
…
Joseph Gut - thasso
Posted in New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
March 21, 2015 – The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recently recommended restrictions on the use of codeine-containing medicines for cough and cold in children because of the risk of serious side effects with these medicines,
…
Joseph Gut - thasso
Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Personalized Medicine, Pharmacogenetics, Thasso Post, Theragenomics
No Comments ↓
September 27, 2014 – A while ago (August 2012), the American Food and Drug Administration (FDA) was assessing and reporting on the (possibly fatal) risks associated with the use of codeine containing medicines in children who are phenotypically members of the CYP2D6 Ultrametabolizer Patient Subgroup because oaf their CYP2D6 genetic background.
…
November 3, 2009 – As we learn from it’s todays announcement, FDA is requiring stronger warnings about an increased risk of lymphoma and other cancers in children and adolescents who are treated with drugs that block tumor necrosis factor. TNF blockers include Infliximab [Remicade], Etanercept [Enbrel], Adalizumab [Humira], Certolizumab [Cimzia],
…
October 30, 2009 – Schizophrenia drugs, increasingly prescribed to children with bipolar disorder and other conditions, can cause youngsters to experience rapid weight gain, according to a new study. Thus, children and adolescents who take the drugs, known as atypical antipsychotics, gain an average of 10 to 19 pounds in the first few months,
…
Optional: Social Subscribe/Login
thasso: recent comments